REYATAZ 200 mg/1

REYATAZ 200 mg/1 is an antiretroviral medication used to manage HIV infection. This gelatin-coated capsule is designed for oral administration and is manufactured by E.R. Squibb & Sons, L.L.C. in the USA.

REYATAZ 200 mg/1 is primarily used as part of a combination therapy to treat HIV infection. It works by inhibiting the protease enzyme, which is essential for the virus to replicate. This medication is often prescribed to help control HIV and reduce the risk of disease progression. Patients should consult their healthcare provider to determine if REYATAZ is suitable for their specific condition.

Common effects of REYATAZ 200 mg/1 may include nausea, vomiting, and diarrhea. Some users might experience changes in body fat distribution or jaundice. It is important to monitor for any unusual symptoms and report them to a healthcare professional.

REYATAZ 200 mg/1 should be stored at room temperature and kept out of reach of children. Patients with liver problems or those taking other medications should discuss potential risks with their healthcare provider. Regular medical check-ups are recommended to monitor the effectiveness and safety of the treatment.

REYATAZ 200 mg/1 may interact with other medications, including certain antacids, antibiotics, and antifungal drugs. Alcohol consumption should be avoided as it can increase the risk of side effects. Patients should inform their healthcare provider about all medications they are taking to avoid potential interactions.